基于动物实验系统评价干细胞治疗肾脏缺血再灌注损伤的可行性.

BACKGROUND: With the in-depth investigation of stem cells and better understanding of kidney ischemia/reperfusion injury, stem cell therapy for renal ischemia/reperfusion injury in animal experiments have been developed extensively, and have achieved certain advance. Therefore, it is necessary to conduct a systematic evaluation to explore the specific efficacy of stem cell therapy for renal ischemia/reperfusion injury. OBJECTIVE: To systematically evaluate the effects of stem cells on the function and structure of the kidney and the immune function of the body and the feasibility of transformation into clinical practice based on the animal experiments. METHODS: Databases of PubMed, Web of Science, Embase, CNKI, VIP and WanFang were searched by computer, and the search time was limited before May 2019. The literature was screened independently by two researchers, and the data were extracted. SYRCLE animal experiment bias risk assessment tool was used to evaluate the methodological quality of the study, and the evidence quality was evaluated using CERQual tool. RESULTS AND CONCLUSION: Finally, 17 animal experiments were included, but there was great clinical heterogeneity among the studies. Therefore, we performed a qualitative description. Compared with the placebo group, the renal function (serum creatinine and blood urea nitrogen level), immune status and renal tissue injury in the stem cell therapy group were improved. But the evidence quality of the six outcome indexes was “low”, and there was a certain risk of bias in the study. The exact efficacy of stem cells and the need for further clinical research cannot be determined due to the problems in experimental design and quality of evidence. Therefore, prior to the inception of clinical trial, high-quality pre-clinical study is necessary to further evaluate the effect of stem cells on renal ischemia/reperfusion injury and the feasibility of clinical transformation to reduce the risk of clinical transformation. [ABSTRACT FROM AUTHOR]